These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37227016)

  • 1. Safety of Inpatient Zoledronic Acid in the Immediate Postfracture Setting.
    Fan W; Leder BZ; Mannstadt M; Ly TV; Franco-Garcia E; Bolster MB
    J Clin Endocrinol Metab; 2023 Oct; 108(11):e1282-e1288. PubMed ID: 37227016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolerability of the first infusion of once-yearly zoledronic acid within one to two weeks after hip fracture surgery.
    Kashii M; Kamatani T; Abe S; Yoshida A; Yamamoto K; Koizumi K; Mizuno N; Kuriyama K; Yoshikawa H
    Bone; 2022 Feb; 155():116298. PubMed ID: 34906743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inpatient Zoledronic Acid and Integrated Orthopedic and Fracture Liaison Services Improve Osteoporosis Treatment Rates.
    Fan W; Machado M; Leder BZ; Beyer L; Garcia EF; Kronenberg HM; Cevallos S; Espinoza J; Finkelstein JS; Bolster MB
    J Clin Endocrinol Metab; 2022 Dec; 108(1):191-197. PubMed ID: 36056816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zoledronic acid for hip fracture during initial hospitalization.
    Fan W; Sun X; Leder BZ; Lee H; Ly TV; Pu CT; Franco-Garcia E; Bolster MB
    J Bone Miner Res; 2024 Aug; 39(8):1061-1070. PubMed ID: 38952014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Short-Term Safety of Zoledronic Acid in Young Patients With Bone Disorders: An Extensive Institutional Experience.
    George S; Weber DR; Kaplan P; Hummel K; Monk HM; Levine MA
    J Clin Endocrinol Metab; 2015 Nov; 100(11):4163-71. PubMed ID: 26308295
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapy.
    Lang JM; Wallace M; Becker JT; Eickhoff JC; Buehring B; Binkley N; Staab MJ; Wilding G; Liu G; Malkovsky M; McNeel DG
    Clin Genitourin Cancer; 2013 Dec; 11(4):407-15. PubMed ID: 23835291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of a single intravenous zoledronic acid administration on biomarkers of acute kidney injury (AKI) in patients with osteoporosis: a pilot study.
    Cipriani C; Pepe J; Clementelli C; Manai R; Colangelo L; Fassino V; Nieddu L; Minisola S
    Br J Clin Pharmacol; 2017 Oct; 83(10):2266-2273. PubMed ID: 28543687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with acetaminophen/paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5 mg.
    Wark JD; Bensen W; Recknor C; Ryabitseva O; Chiodo J; Mesenbrink P; de Villiers TJ
    Osteoporos Int; 2012 Feb; 23(2):503-12. PubMed ID: 21331467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of renal failure in cancer patients with bone metastasis treated with renally adjusted zoledronic acid.
    Shah SR; Jean GW; Keisner SV; Ussery SM; Dowell JE
    Support Care Cancer; 2012 Jan; 20(1):87-93. PubMed ID: 21197550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous zoledronic Acid given every 6 months in childhood osteoporosis.
    Ooi HL; Briody J; Biggin A; Cowell CT; Munns CF
    Horm Res Paediatr; 2013; 80(3):179-84. PubMed ID: 24052046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of intravenous zoledronic acid infusion on electrocardiographic parameters in patients with osteoporosis.
    Aktas I; Nazikoglu C; Kepez A; Ozkan FU; Kaysin MY; Akpinar P; Dogan Z; Ileri C; Saymaz S; Erdogan O
    Osteoporos Int; 2016 Dec; 27(12):3543-3547. PubMed ID: 27344642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toxicity of zoledronic acid after intravenous administration: A retrospective study of 95 dogs.
    Brewer DJ; Macfarlane M; O'Connell E; Bacon NJ
    J Vet Intern Med; 2022 Jan; 36(1):253-258. PubMed ID: 34859920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Case of Severe, Prolonged, Refractory Hypophosphatemia After Zoledronic Acid Administration.
    Clark SL; Nystrom EM
    J Pharm Pract; 2016 Apr; 29(2):172-6. PubMed ID: 26739479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zoledronic acid and clinical fractures and mortality after hip fracture.
    Lyles KW; Colón-Emeric CS; Magaziner JS; Adachi JD; Pieper CF; Mautalen C; Hyldstrup L; Recknor C; Nordsletten L; Moore KA; Lavecchia C; Zhang J; Mesenbrink P; Hodgson PK; Abrams K; Orloff JJ; Horowitz Z; Eriksen EF; Boonen S;
    N Engl J Med; 2007 Nov; 357(18):1799-809. PubMed ID: 17878149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal safety of zoledronic acid administration beyond 24 months in breast cancer patients with bone metastases.
    Dincer M; Altundag K; Harputluoglu H; Aksoy S; Cengiz M; Gullu I
    Med Oncol; 2008; 25(3):356-9. PubMed ID: 18196480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-year follow-up of a randomized controlled trial of immediate versus delayed zoledronic acid for the prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen: N03CC (Alliance) trial.
    Wagner-Johnston ND; Sloan JA; Liu H; Kearns AE; Hines SL; Puttabasavaiah S; Dakhil SR; Lafky JM; Perez EA; Loprinzi CL
    Cancer; 2015 Aug; 121(15):2537-43. PubMed ID: 25930719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-induced hepatotoxicity linked to zoledronic acid in the treatment of an elderly man with primary osteoporosis.
    Chen W; Zhu M
    Int J Clin Pharmacol Ther; 2021 Nov; 59(11):721-724. PubMed ID: 34423770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of acetaminophen and fluvastatin on post-dose symptoms following infusion of zoledronic acid.
    Silverman SL; Kriegman A; Goncalves J; Kianifard F; Carlson T; Leary E
    Osteoporos Int; 2011 Aug; 22(8):2337-45. PubMed ID: 21116816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transient changes in thyroid functions tests after zoledronic acid infusion.
    Karga H; Giagourta I; Papaioannou G; Katsichti P; Pardalakis A; Kassi G; Zagoreou A; Triantaphyllopoulou M; Zerva C
    Endocr J; 2011; 58(11):969-77. PubMed ID: 21891972
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS).
    Wirth M; Tammela T; Cicalese V; Gomez Veiga F; Delaere K; Miller K; Tubaro A; Schulze M; Debruyne F; Huland H; Patel A; Lecouvet F; Caris C; Witjes W
    Eur Urol; 2015 Mar; 67(3):482-91. PubMed ID: 24630685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.